Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Drouet

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Bulletin De L'Academie Nationale De Medecine|October 15, 2003
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]Ludovic Drouet
Cerebrovascular Diseases (Basel, Switzerland)|January 23, 2002
Atherothrombosis as a systemic diseaseLudovic Drouet
La Revue Du Praticien|March 11, 2008
[Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents]Ludovic Drouet
Targeted Oncology|January 26, 2012
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?Ludovic Drouet
La Revue Du Praticien|June 10, 2003
[Diagnosing disorders of hemostasis and coagulation]Ludovic Drouet
La Revue Du Praticien|April 4, 2003
[New and future antithrombotic agents in thrombo-embolic venous disease]Ludovic Drouet
Medecine Sciences : M/S|October 10, 2006
[Targets of antithrombotic drugs]Ludovic Drouet, Laurent Ripoll
Therapie|June 23, 2005
[Is fibrinogen a predictor or a marker of the risk of cardiovascular events?]Ludovic Drouet, Claire Bal dit Sollier
La Revue Du Praticien|May 6, 2015
[The anticoagulation clinics]Claire Bal dit Sollier, Ludovic Drouet
Thrombosis and Haemostasis|September 13, 2020
The Multiple Faces of Heparin: Opportunities in COVID-19 Infection and BeyondLudovic Drouet, Job Harenberg, Giangiacomo Torri
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Bulletin De L'Academie Nationale De Medecine|October 15, 2003
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]Ludovic Drouet
Cerebrovascular Diseases (Basel, Switzerland)|January 23, 2002
Atherothrombosis as a systemic diseaseLudovic Drouet
La Revue Du Praticien|March 11, 2008
[Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents]Ludovic Drouet
Targeted Oncology|January 26, 2012
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?Ludovic Drouet
La Revue Du Praticien|June 10, 2003
[Diagnosing disorders of hemostasis and coagulation]Ludovic Drouet
La Revue Du Praticien|April 4, 2003
[New and future antithrombotic agents in thrombo-embolic venous disease]Ludovic Drouet
Medecine Sciences : M/S|October 10, 2006
[Targets of antithrombotic drugs]Ludovic Drouet, Laurent Ripoll
Therapie|June 23, 2005
[Is fibrinogen a predictor or a marker of the risk of cardiovascular events?]Ludovic Drouet, Claire Bal dit Sollier
La Revue Du Praticien|May 6, 2015
[The anticoagulation clinics]Claire Bal dit Sollier, Ludovic Drouet
Thrombosis and Haemostasis|September 13, 2020
The Multiple Faces of Heparin: Opportunities in COVID-19 Infection and BeyondLudovic Drouet, Job Harenberg, Giangiacomo Torri
Pageof 12